Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

INTRODUCTION: Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Vijiaratnam, Nirosen, Girges, Christine, Auld, Grace, Chau, Marisa, Maclagan, Kate, King, Alexa, Skene, Simon, Chowdhury, Kashfia, Hibbert, Steve, Morris, Huw, Limousin, Patricia, Athauda, Dilan, Carroll, Camille B, Hu, Michele T, Silverdale, Monty, Duncan, Gordon W, Chaudhuri, Ray, Lo, Christine, Del Din, Silvia, Yarnall, Alison J, Rochester, Lynn, Gibson, Rachel, Dickson, John, Hunter, Rachael, Libri, Vincenzo, Foltynie, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://ncbi.nlm.nih.gov/pubmed/34049922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-047993
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados